Kishbauch joins Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) board


Dallas, Texas 09/16/2013 (Financialstrend) – Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has announced that an innovative and highly-experienced leader in the health-care industry, Michael D. Kishbauch,

has been elected to the company’s Board of Directors. Stephen P. Goff, Ph.D., who had been  on the Board since the year 1993, has retired. Kishbauch has been in the industry for close to three decades and has held very senior management-positions in the life-sciences industry.  Most recently, he was the President and Chief Executive officer of Achillion Pharmaceuticals

Mr. Kishbauch has vast operational, product-planning, strategic, promotion, marketing sales  and product-launch experience. Before Achillion, he founded and served as President and CEO of OraPharma. This is a publicly-traded, commercial-stage pharma company that focuses on oral health care. Johnson & Johnson acquired OraPharma.

 Friday’s trading

In Friday’s trading, Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) stock rose by 2.63%. The opening price of the shares was $   5.73 which touched an intraday high of $5.92 and dipped to close at $5.85. Approximately 0.933 million shares were traded on Friday while the average volume of shares traded over 30 days was 0.558. The company has a market cap of $355.82 million.

About the company

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) is a bio-pharma company. It  focuses on R&D for bio-technology product candidates in the fields of virology, oncology, supportive-care and gastroenterology. The company is also involved in  research to identify multiplex-phosphoinositide 3-kinase inhibitors that are used in blocking signaling-pathways in the growth of various aggressive cancers.

In gastroenterology, the company’s 1st commercial product  RELISTOR is a subcutaneous injection. PSMA ADC is its primary product candidate. This fully-human monoclonal antibody drug-conjugate is directed against prostate-specific membrane antigen. This is a protein that is found at very high levels on the surface of the prostate cancer cells. It is also found on the neovasculature of numerous types of solid tumors. In 2013 January 2013, Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) acquired Molecular Insight Pharmaceuticals.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.